Lixisenatide resensitizes the insulin-secretory response to intravenous glucose challenge in people with type 2 diabetes - a study in both people with type 2 diabetes and healthy subjects+.
Becker, R. H. A. 1; Stechl, J. 1; Msihid, J. 2; Kapitza, C. 3
[Article] Diabetes, Obesity & Metabolism. 16(9):793-800, September 2014.

(Format: HTML, PDF)